CClinicalTrials.gg
CompletedNCT05982509Updated Aug 8, 2023

Clinical Trial to Assess the Efficacy and Safety of EASYDEW MD REGEN Cream Containing Neopop-S.

An interventional study of EasyDew Regen MD Cream in Laser-Induced Scar, sponsored by Eun-ji Kim. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-08-08.

Sponsored by Eun-ji Kim · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Nov 2022, registered Jul 2023).
Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
19 Years to 65 Years
Sex
All
01

Study summary

The purpose of this clinical study is to evaluate the effect on skin regeneration after applying EasyDew MD Regen Cream containing Neopep-S, a regeneration factor, to patients who have undergone picosure picosure laser skin treatment as needed.

Read the detailed description

This clinical study is a researcher-led randomized control group comparative clinical study that is conducted prospectively for one month after applying medical devices for clinical research.

The subjects are those who have undergone a picosure laser procedure for therapeutic purposes on the skin tissue of the face or body, and a screening test is conducted after the subject (and/or legal representative) agrees in writing to participate in the clinical study.

The screening test results are evaluated, and subjects who meet the selection criteria and do not meet the exclusion criteria are registered in clinical research.

Participating subjects are randomly assigned to the control group and the study group using a random number table at a 5:5 ratio.

  • Control group: 10 people without treatment
  • Study Group: 10 People Applying EasyDu Regen MD Cream Clinical study subjects are randomly assigned to control and study groups. In the case of the study group, the Easy Dew Regen MD cream provided through prescription is applied twice a day (morning and evening) to the skin of the area where the picosure laser treatment has been performed and absorbed well. The control group is the non-chalant group. However, general moisturizers that were used at home rather than medical devices for one month after the procedure can be used, and they are applied twice a day (morning and evening) to the skin of the area where the laser treatment has been performed and absorbed well.

One month of clinical research medical device application will be observed, and subjects will regularly visit the research institution to evaluate its validity and safety during screening visits (Visit1), treatment (Visit2), 2 weeks after treatment (Visit3), and 1 month after treatment (Visit3) You will receive it.

02

Conditions studied

  • Laser-Induced Scar
03

In context

Lead sponsor

Eun-ji Kim is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Those aged 19 to 65 who have undergone picosure laser treatment on facial and body skin tissues
  • Decided to participate in this clinical study and signed a written informed consent the subject

Exclusion criteria

Exclusion Criteria:

  • Subjects with uncontrolled diabetes
  • Subjects with uncontrolled hypertension and cardiovascular disease
  • Subjects with hemorrhagic diseases such as hemophilia
  • Immunosuppressants, corticosteroids, cytotoxic agents, and anticoagulants can affect the results Subjects who are or are scheduled to receive medication for an extended period of time
  • Acute or chronic skin disease causes stage progression or active bacteria in the application area Who has a virus infection
  • When the researcher's judgment determines that participation in the study is inappropriate (e.g. keloid constitution)
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • No intervention
    No intervention

    Control group: 10 people without treatment

  • Experimental
    Treatment

    Study Group: 10 People Applying EasyDew Regen MD Cream

    Device: EasyDew Regen MD Cream

Interventions

  • DeviceEasyDew Regen MD Cream

    For the study group, I received the prescription Easy Dew Regen MD Cream from Picosure Laser Apply an appropriate amount twice a day (morning and evening) to the skin of the area so that it can be absorbed well do. The control group is the non-chalant group. However, for one month after the procedure, it is not a medical device The normal moisturizer you use at home is available, and the area where you have undergone laser treatment Apply it twice a day (morning and evening) to the skin so that it can be absorbed well.

06

What researchers measure

Primary outcomes

  1. Transepidermal water loss Transcutaneous water loss (TEWL) measured

    Before, immediately after treatment, and one month after application of the medical device Transcutaneous water loss (TEWL) measured

    Time frame: Before, immediately after treatment, and one month after application

07

Study locations

1 site
  • Ajou University Hospital
    Gyeonggi-do, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 8, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05982509
Lead sponsor
Eun-ji Kim
Responsible party
Eun-ji Kim (Clinical Trial Manager, CGBio Inc.) — Sponsor-investigator
First posted
Aug 8, 2023
Start date
Nov 11, 2022
Primary completion
Jul 27, 2023
Completion
Jul 27, 2023
Last update
Aug 8, 2023

Study contacts

Jihye Lee
study director · CGBio Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion